PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

minocycline Side Effects

The reactions most often reported to the FDA for minocycline (also sold as Minocin, Solodyn), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

11,257
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of minocycline come from 11,257 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 11,257 reports to the FDA Adverse Event Reporting System (FAERS) for minocycline (Minocin): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

11,257

Reports Mentioning Death

1,508

13.4% of reports — not proof the medicine caused the death

Hospitalizations

3,578

31.8% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

NAUSEA
1,029
PAIN
987
ARTHRALGIA
960
FATIGUE
913
DRUG HYPERSENSITIVITY
867
RASH
867
RHEUMATOID ARTHRITIS
834
JOINT SWELLING
833
HEADACHE
767
CONDITION AGGRAVATED
719
PNEUMONIA
718
DIARRHOEA
702
GENERAL PHYSICAL HEALTH DETERIORATION
647
DIZZINESS
642
HYPERTENSION
632
ABDOMINAL DISCOMFORT
593
C-REACTIVE PROTEIN INCREASED
589

Who Reports Side Effects

Gender Distribution

Female 6,489 (64%)
Male 3,574 (35%)
Unknown 35

Age Distribution

0-17 967 (12%)
18-44 2,924 (37%)
45-64 2,281 (29%)
65-74 1,113 (14%)
75+ 703 (9%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 1,508 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
C-REACTIVE PROTEIN INCREASED 424
PAIN 423
PNEUMONIA 419
HYPERTENSION 412
GENERAL PHYSICAL HEALTH DETERIORATION 407
INFUSION RELATED REACTION 404
HYPOAESTHESIA 403
MATERNAL EXPOSURE DURING PREGNANCY 403
HEPATIC ENZYME INCREASED 397
MOBILITY DECREASED 394
PEMPHIGUS 394
RHEUMATOID ARTHRITIS 392
ARTHRALGIA 391
GLOSSODYNIA 390
PSORIATIC ARTHROPATHY 387
DRUG HYPERSENSITIVITY 386

Reactions in Hospitalization Reports

Top reactions in 3,578 reports where hospitalization was an outcome.

Reaction Reports
PAIN 600
NAUSEA 573
FATIGUE 520
PNEUMONIA 511
HEADACHE 473
JOINT SWELLING 472
C-REACTIVE PROTEIN INCREASED 466
RASH 462
HYPERTENSION 451
GENERAL PHYSICAL HEALTH DETERIORATION 448
ARTHRALGIA 436
DRUG HYPERSENSITIVITY 435
CONDITION AGGRAVATED 434
ARTHROPATHY 432
ABDOMINAL DISCOMFORT 430
MOBILITY DECREASED 423
MALAISE 415
RHEUMATOID ARTHRITIS 415

Compare minocycline vs amikacin →

What the FAERS Data Reveals About minocycline Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 11,257 voluntary reports linked to minocycline and its brand equivalents (Minocin, Solodyn), spanning 2004 through 2025. Of those, 1,508 (13.4%) listed death as an outcome and 3,578 (31.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 64% were female and 35% male; age distribution skews toward 18-44, with 2,924 reports in that bracket. The single most reported reaction is nausea with 1,029 submissions, followed by pain and arthralgia.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.